In Silico Protein Design Market Report 2025

The in silico protein design market size has grown exponentially in recent years. It will grow from $1.54 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 21.4%. Growth in the historic period was driven by rising awareness of protein therapeutics, growing interest in advanced immunotherapies, increasing demand for sustainable and eco-friendly biotechnology solutions, stronger focus on enhancing drug efficacy through protein design, and greater use of cloud-based technologies in research.

The in silico protein design market size is expected to see exponential growth in the next few years. It will grow to $4.02 billion in 2029 at a compound annual growth rate (CAGR) of 21.1%. Growth in the forecast period is expected to result from expanding applications of machine learning in protein modeling, increased investment in computational biology, greater demand for cost-effective drug discovery approaches, rising emphasis on precision medicine, and growing demand for biopharmaceuticals. Key trends anticipated for the forecast period include advancements in AI-driven protein modeling, integration of quantum computing, development of automated protein design platforms, innovation in de novo protein synthesis, and progress in multi-omics data integration.

The growing demand for personalized medicine is expected to drive the growth of the in silico protein design market in the coming years. Personalized medicine tailors medical treatments and prevention strategies to an individual’s genetic profile, lifestyle, and environmental factors. This demand is increasing due to advancements in genomic technologies and the growing adoption of value-based care models, which focus on improving patient outcomes while reducing overall healthcare costs. In silico protein design supports personalized medicine by enabling the rapid creation of customized therapeutic proteins that are tailored to specific patient needs. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant rise from six approvals in 2022. This surge in demand for personalized medicine is fueling the growth of the in silico protein design market.

Companies in the in silico protein design market are developing advanced solutions, such as push-button protein design platforms, to speed up drug discovery, enhance therapeutic efficacy, and facilitate the creation of novel biologics. Push-button protein design platforms are automated tools that allow researchers to quickly design and modify proteins with minimal manual intervention. For instance, in July 2025, UK-based biotechnology company Latent Labs launched Latent-X, a generative AI model that enables users with no coding expertise to upload targets and design macrocycles and mini-binders at the atomic level. This platform delivers high hit rates for macrocycles and mini-binders and achieves picomolar to micromolar binding affinities with lab-verified specificity. The system also produces complete protein sequences and structures much faster than previous methods, making it a significant leap forward in protein therapeutics and accelerating innovation in the field.

In July 2023, BioNTech SE, a German biotechnology company, acquired InstaDeep Ltd. to strengthen its AI capabilities. This acquisition combines BioNTech’s expertise in immunotherapy and vaccine development with InstaDeep’s advanced artificial intelligence and machine learning technologies, enhancing AI-powered drug discovery and development. The partnership aims to improve the creation of innovative therapies, particularly in cancer and infectious diseases. InstaDeep Ltd., a UK-based company, is known for its in silico protein design technologies, and this acquisition is expected to accelerate the development of cutting-edge therapeutics.

Major players in the in silico protein design market are Dassault Systèmes SE, Schrödinger Inc., Generate Biomedicines Inc., Insilico Medicine Inc., Chemical Computing Group ULC, Arzeda Corp., Outpace Bio Inc., Evozyne Inc., Cradle Bio B.V., Seismic Therapeutics Inc., Profluent Bio Inc., Nabla Bio Inc., Antiverse Ltd., EvolutionaryScale Inc., RevolKa Ltd., Molecular Discovery Ltd., Inte:Ligand GmbH, Kuano Ltd., AI Proteins Inc., and Menten AI Inc.

North America was the largest region in the in silico protein design market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in in silico protein design report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the in silico protein design market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

In silico protein design is the process of creating or modifying protein structures using computer-based modeling and simulations rather than laboratory experiments. It employs computational tools to predict how amino acid sequences will fold and interact, enabling the design of proteins with specific shapes and functions. This approach accelerates discovery, reduces costs, and allows researchers to explore numerous possibilities before experimental validation.

The primary software types for in silico protein design include cloud-based software and on-premise software. Cloud-based software refers to digital platforms that operate over the internet, providing access to advanced protein design applications without requiring installation or maintenance on local computers. These tools incorporate technologies such as molecular modeling, artificial intelligence and machine learning algorithms, homology modeling, and others. Applications include drug discovery and development, enzyme engineering, biomarker discovery, vaccinology, and academic research. End users include pharmaceutical and biotechnology companies, academic and research institutions, and others.

The in silico protein design market research report is one of a series of new reports that provides in silico protein design market statistics, including in silico protein design industry global market size, regional shares, competitors with a in silico protein design market share, detailed in silico protein design market segments, market trends and opportunities, and any further data you may need to thrive in the in silico protein design industry. This in silico protein design market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The in silico protein design market consists of revenues earned by entities by providing services such as protein structure modelling, protein engineering and optimization, antibody and biologic design, molecular docking, and virtual screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The in silico protein design market also includes sales of optimized proteins, enzyme variants, peptides and vaccine candidates, protein models, and research kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.